MedTrace Logo

Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma

NCT01948180 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2019-03-13

No results posted yet for this study

Summary

To investigate the efficacy of autologous EBV-specific T-cells for the treatment of patients with aggressive EBV positive extranodal NK/T-cell lymphoma

Conditions

  • Lymphoma, Extranodal NK-T-Cell
  • EBV

Interventions

BIOLOGICAL

baltaleucel-T

Autologous EBV-specific T-cells

Sponsors & Collaborators

  • Cell Medica Ltd

    lead INDUSTRY

Principal Investigators

  • Helen Heslop, MD · Baylor College of Medicine

  • Kurt Gunter, MD · Cell Medica

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2018-04-16
Completion
2018-09-07

Countries

  • United States
  • France
  • South Korea
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01948180 on ClinicalTrials.gov